Research ExplorerPublicationsImpact of preoperative plasma levels of interleukin 6 and in...

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer

Standard

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. / Schuettfort, Victor M; Pradere, Benjamin; Trinh, Quoc-Dien; D'Andrea, David; Quhal, Fahad; Mostafaei, Hadi; Laukhtina, Ekaterina; Mori, Keiichiro; Sari Motlagh, Reza; Rink, Michael; Karakiewicz, Pierre I; Chlosta, Piotr; Yuen-Chun Teoh, Jeremy; Lotan, Yair; Scherr, Douglas; Abufaraj, Mohammad; Moschini, Marco; Shariat, Shahrokh F.

In: CANCER IMMUNOL IMMUN, Vol. 71, No. 1, 01.2022, p. 85-95.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schuettfort, VM, Pradere, B, Trinh, Q-D, D'Andrea, D, Quhal, F, Mostafaei, H, Laukhtina, E, Mori, K, Sari Motlagh, R, Rink, M, Karakiewicz, PI, Chlosta, P, Yuen-Chun Teoh, J, Lotan, Y, Scherr, D, Abufaraj, M, Moschini, M & Shariat, SF 2022, 'Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer', CANCER IMMUNOL IMMUN, vol. 71, no. 1, pp. 85-95. https://doi.org/10.1007/s00262-021-02953-0

APA

Schuettfort, V. M., Pradere, B., Trinh, Q-D., D'Andrea, D., Quhal, F., Mostafaei, H., Laukhtina, E., Mori, K., Sari Motlagh, R., Rink, M., Karakiewicz, P. I., Chlosta, P., Yuen-Chun Teoh, J., Lotan, Y., Scherr, D., Abufaraj, M., Moschini, M., & Shariat, S. F. (2022). Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. CANCER IMMUNOL IMMUN, 71(1), 85-95. https://doi.org/10.1007/s00262-021-02953-0

Vancouver

Schuettfort VM, Pradere B, Trinh Q-D, D'Andrea D, Quhal F, Mostafaei H et al. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. CANCER IMMUNOL IMMUN. 2022 Jan;71(1):85-95. https://doi.org/10.1007/s00262-021-02953-0

Bibtex

@article{2995eb506e47424c9191f85b2d7881f7,
title = "Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer",
abstract = "BACKGROUND: Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB is missing.PATIENTS/METHODS: We prospectively collected preoperative plasma from 1,036 consecutive patients at two institutes. These plasma specimens were assessed for levels of IL6 and IL6sR. Logistic and Cox regression analyses were used to assess the correlation of plasma levels with pathologic and survival outcomes. The additional clinical net benefits of preoperative IL6 and IL6sR were evaluated using decision curve analysis (DCA).RESULTS: Median IL6 and IL6sR plasma levels were significantly higher in patients with adverse pathologic features. Elevated biomarker levels were independently associated with an increased risk for lymph node metastasis and ≥ pT3 disease. Both biomarkers were independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The addition to, respectively, fitted pre- and postoperative prognostic models improved the predictive accuracy for lymph node metastasis, ≥ pT3 disease, RFS and CSS on DCA.INTERPRETATION: We confirmed that elevated preoperative plasma levels of IL6 and IL6sR levels are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers hold potential in identifying patients with adverse pathological features that may benefit from intensified/multimodal therapy and warrant inclusion into predictive/prognostic models. They demonstrated the ability to improve the discriminatory power of such models and thus guide clinical decision making.",
author = "Schuettfort, {Victor M} and Benjamin Pradere and Quoc-Dien Trinh and David D'Andrea and Fahad Quhal and Hadi Mostafaei and Ekaterina Laukhtina and Keiichiro Mori and {Sari Motlagh}, Reza and Michael Rink and Karakiewicz, {Pierre I} and Piotr Chlosta and {Yuen-Chun Teoh}, Jeremy and Yair Lotan and Douglas Scherr and Mohammad Abufaraj and Marco Moschini and Shariat, {Shahrokh F}",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = jan,
doi = "10.1007/s00262-021-02953-0",
language = "English",
volume = "71",
pages = "85--95",
journal = "CANCER IMMUNOL IMMUN",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

RIS

TY - JOUR

T1 - Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer

AU - Schuettfort, Victor M

AU - Pradere, Benjamin

AU - Trinh, Quoc-Dien

AU - D'Andrea, David

AU - Quhal, Fahad

AU - Mostafaei, Hadi

AU - Laukhtina, Ekaterina

AU - Mori, Keiichiro

AU - Sari Motlagh, Reza

AU - Rink, Michael

AU - Karakiewicz, Pierre I

AU - Chlosta, Piotr

AU - Yuen-Chun Teoh, Jeremy

AU - Lotan, Yair

AU - Scherr, Douglas

AU - Abufaraj, Mohammad

AU - Moschini, Marco

AU - Shariat, Shahrokh F

N1 - © 2021. The Author(s).

PY - 2022/1

Y1 - 2022/1

N2 - BACKGROUND: Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB is missing.PATIENTS/METHODS: We prospectively collected preoperative plasma from 1,036 consecutive patients at two institutes. These plasma specimens were assessed for levels of IL6 and IL6sR. Logistic and Cox regression analyses were used to assess the correlation of plasma levels with pathologic and survival outcomes. The additional clinical net benefits of preoperative IL6 and IL6sR were evaluated using decision curve analysis (DCA).RESULTS: Median IL6 and IL6sR plasma levels were significantly higher in patients with adverse pathologic features. Elevated biomarker levels were independently associated with an increased risk for lymph node metastasis and ≥ pT3 disease. Both biomarkers were independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The addition to, respectively, fitted pre- and postoperative prognostic models improved the predictive accuracy for lymph node metastasis, ≥ pT3 disease, RFS and CSS on DCA.INTERPRETATION: We confirmed that elevated preoperative plasma levels of IL6 and IL6sR levels are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers hold potential in identifying patients with adverse pathological features that may benefit from intensified/multimodal therapy and warrant inclusion into predictive/prognostic models. They demonstrated the ability to improve the discriminatory power of such models and thus guide clinical decision making.

AB - BACKGROUND: Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB is missing.PATIENTS/METHODS: We prospectively collected preoperative plasma from 1,036 consecutive patients at two institutes. These plasma specimens were assessed for levels of IL6 and IL6sR. Logistic and Cox regression analyses were used to assess the correlation of plasma levels with pathologic and survival outcomes. The additional clinical net benefits of preoperative IL6 and IL6sR were evaluated using decision curve analysis (DCA).RESULTS: Median IL6 and IL6sR plasma levels were significantly higher in patients with adverse pathologic features. Elevated biomarker levels were independently associated with an increased risk for lymph node metastasis and ≥ pT3 disease. Both biomarkers were independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The addition to, respectively, fitted pre- and postoperative prognostic models improved the predictive accuracy for lymph node metastasis, ≥ pT3 disease, RFS and CSS on DCA.INTERPRETATION: We confirmed that elevated preoperative plasma levels of IL6 and IL6sR levels are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers hold potential in identifying patients with adverse pathological features that may benefit from intensified/multimodal therapy and warrant inclusion into predictive/prognostic models. They demonstrated the ability to improve the discriminatory power of such models and thus guide clinical decision making.

U2 - 10.1007/s00262-021-02953-0

DO - 10.1007/s00262-021-02953-0

M3 - SCORING: Journal article

C2 - 34023914

VL - 71

SP - 85

EP - 95

JO - CANCER IMMUNOL IMMUN

JF - CANCER IMMUNOL IMMUN

SN - 0340-7004

IS - 1

ER -